Here are the 10-K annual reports from Maravai LifeSciences Holdings, Inc. (MRVI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MRVI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRVI filings page.
Maravai LifeSciences Holdings, Inc. reports its 2025 business overview, risk profile and strategy as a specialized life sciences supplier to drug, vaccine and diagnostics developers. The company operates through two segments: TriLink, focused on mRNA and nucleic acids, generated 64% of 2025 revenue, while Cygnus, focused on biologics safety testing, contributed 36%.
Key products include CleanCap® mRNA capping, ModTail™ poly(A) technology, custom mRNA and GMP manufacturing, and Cygnus host cell protein ELISA and MockV® viral clearance tools, backed by an extensive global patent portfolio. As of December 31, 2025, Maravai had 435 full-time employees and an aggregate non‑affiliate market value of about $300.0 million. High-volume CleanCap® sales for commercial vaccine programs fell to about 0.0% of 2025 revenue after representing 25.4% in 2024 and 21.0% in 2023, highlighting demand volatility.
In 2025 the company renamed its segments to align with its TriLink and Cygnus brands, adopted AI- and machine-learning–based design tools, and launched a Corporate Realignment Plan that includes cutting roughly 25% of the workforce and reducing facilities to lower costs and refocus on long-term growth.